1. Home
  2. TECH vs PCVX Comparison

TECH vs PCVX Comparison

Compare TECH & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bio-Techne Corp

TECH

Bio-Techne Corp

HOLD

Current Price

$43.55

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Logo Vaxcyte Inc.

PCVX

Vaxcyte Inc.

HOLD

Current Price

$52.80

Market Cap

7.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECH
PCVX
Founded
1976
2013
Country
United States
United States
Employees
N/A
507
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
7.8B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
TECH
PCVX
Price
$43.55
$52.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
4
Target Price
$71.82
$88.25
AVG Volume (30 Days)
2.8M
1.3M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
0.62%
N/A
EPS Growth
N/A
N/A
EPS
0.81
N/A
Revenue
$1,219,635,000.00
N/A
Revenue This Year
$2.49
N/A
Revenue Next Year
$6.40
N/A
P/E Ratio
$55.27
N/A
Revenue Growth
5.23
N/A
52 Week Low
$44.12
$29.10
52 Week High
$72.16
$65.00

Technical Indicators

Market Signals
Indicator
TECH
PCVX
Relative Strength Index (RSI) 32.35 36.95
Support Level N/A $52.04
Resistance Level $58.41 $56.04
Average True Range (ATR) 3.19 2.51
MACD -1.08 -0.51
Stochastic Oscillator 1.31 33.53

Price Performance

Historical Comparison
TECH
PCVX

About TECH Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Share on Social Networks: